Natalia Baran: Metabolic Rewiring of leukemic cells upon gaining resistance to AraC
Natalia Baran, Assistant Professor in the Department of Leukemia at the UT MD Anderson Cancer Center, shared a post on LinkedIn:
“I am very happy to finalize this very productive year of work with one more published project entitled: Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro, authored by Katie Hege Hurrish, Ph.D. et al. in Biochemical Pharmacology Elsevier for Life Sciences. Here we investigated Metabolic Rewiring of leukemic cells upon gaining resistance to AraC and we examined an efficacy of bcl2 inhibitor venetoclax with a potent isoflavone ME344 in suppressing Oxidative Phosphorylation and its impact on cell death induction.
It was fantastic collaboration between Leukemia Department at MD Anderson and Department of Oncology at Wayne State University School of Medicine.
Kudos to the entire team of very talented and hard-working researchers.
Special thanks to co-corresponding authors Marina Konopleva and Yubin Ge and to Sandra Wiley at MEIpharma.”
For details click here.
Source: Natalia Baran/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023